Biotech company SpliceBio, members of CataloniaBio & HealthTech, has announced the appointment of David Favre, D.V.M., Ph.D., as Chief Development Officer (CDO). Dr. Favre brings extensive experience in gene therapy, immunology and drug development. 

Miquel Vila-Perelló, CEO and co-founder of SpliceBio, said: "I am delighted to welcome David to the SpliceBio leadership team at an exciting time of expansion of the platform as we begin preparations for clinical development. His extensive background in gene therapy, immunology and drug development will be invaluable as he leads the development of the company's therapeutic candidates from pre-clinical research to the clinic. David will focus on advancing the company's leading AAV gene therapy programme for Stargardt disease into clinical development and expanding the company's protein splicing platform and pipeline to other genes beyond the packaging capabilities of AAV vectors. 

David Favre, SpliceBio's new CDO, commented: "SpliceBio has built an impressive gene therapy platform that addresses one of the most fundamental challenges facing the gene therapy field today: the limited packaging capacity of AAV vectors: I am delighted to join SpliceBio's management team to lead the development of several new programmes targeting diseases that have been elusive in gene therapy to date." 

More information 

Photo: The management team at SpliceBio, Gerard Caelles (Chief Business Officer), Miquel Vila-Perelló (Co-founder & CEO), Silvia Frutos (Co-founder & CTO)